230 related articles for article (PubMed ID: 23055022)
1. Expression patterns of Thymosin β4 and cancer stem cell marker CD133 in ovarian cancers.
Ji YI; Lee BY; Kang YJ; Jo JO; Lee SH; Kim HY; Kim YO; Lee C; Koh SB; Kim A; Lee JY; Jung MH; Ock MS; Cha HJ
Pathol Oncol Res; 2013 Apr; 19(2):237-45. PubMed ID: 23055022
[TBL] [Abstract][Full Text] [Related]
2. Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells.
Kryczek I; Liu S; Roh M; Vatan L; Szeliga W; Wei S; Banerjee M; Mao Y; Kotarski J; Wicha MS; Liu R; Zou W
Int J Cancer; 2012 Jan; 130(1):29-39. PubMed ID: 21480217
[TBL] [Abstract][Full Text] [Related]
3. DDX4 (DEAD box polypeptide 4) colocalizes with cancer stem cell marker CD133 in ovarian cancers.
Kim KH; Kang YJ; Jo JO; Ock MS; Moon SH; Suh DS; Yoon MS; Park ES; Jeong N; Eo WK; Kim HY; Cha HJ
Biochem Biophys Res Commun; 2014 May; 447(2):315-22. PubMed ID: 24727449
[TBL] [Abstract][Full Text] [Related]
4. Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases.
Jing F; Kim HJ; Kim CH; Kim YJ; Lee JH; Kim HR
Int J Oncol; 2015 Apr; 46(4):1582-8. PubMed ID: 25625240
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.
Baba T; Convery PA; Matsumura N; Whitaker RS; Kondoh E; Perry T; Huang Z; Bentley RC; Mori S; Fujii S; Marks JR; Berchuck A; Murphy SK
Oncogene; 2009 Jan; 28(2):209-18. PubMed ID: 18836486
[TBL] [Abstract][Full Text] [Related]
6. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival.
Silva IA; Bai S; McLean K; Yang K; Griffith K; Thomas D; Ginestier C; Johnston C; Kueck A; Reynolds RK; Wicha MS; Buckanovich RJ
Cancer Res; 2011 Jun; 71(11):3991-4001. PubMed ID: 21498635
[TBL] [Abstract][Full Text] [Related]
7. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer.
Curley MD; Therrien VA; Cummings CL; Sergent PA; Koulouris CR; Friel AM; Roberts DJ; Seiden MV; Scadden DT; Rueda BR; Foster R
Stem Cells; 2009 Dec; 27(12):2875-83. PubMed ID: 19816957
[TBL] [Abstract][Full Text] [Related]
8. Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer.
Qin Q; Sun Y; Fei M; Zhang J; Jia Y; Gu M; Xia R; Chen S; Deng A
Neoplasma; 2012; 59(3):310-5. PubMed ID: 22296500
[TBL] [Abstract][Full Text] [Related]
9. Expression of CD133 and CD117 in 64 Serous Ovarian Cancer Cases.
Stemberger-Papić S; Vrdoljak-Mozetic D; Ostojić DV; Rubesa-Mihaljević R; Krigtofić I; Brncić-Fisher A; Kragević M; Eminović S
Coll Antropol; 2015 Sep; 39(3):745-53. PubMed ID: 26898076
[TBL] [Abstract][Full Text] [Related]
10. Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer.
Kim ST; Sohn I; DO IG; Jang J; Kim SH; Jung IH; Park JO; Park YS; Talasaz A; Lee J; Kim HC
Cancer Genomics Proteomics; 2014; 11(5):259-66. PubMed ID: 25331798
[TBL] [Abstract][Full Text] [Related]
11. Expression of CD133-1 and CD133-2 in ovarian cancer.
Ferrandina G; Bonanno G; Pierelli L; Perillo A; Procoli A; Mariotti A; Corallo M; Martinelli E; Rutella S; Paglia A; Zannoni G; Mancuso S; Scambia G
Int J Gynecol Cancer; 2008; 18(3):506-14. PubMed ID: 17868344
[TBL] [Abstract][Full Text] [Related]
12. Co-expression of stem cell genes CD133 and CD44 in colorectal cancers with early liver metastasis.
Huang X; Sheng Y; Guan M
Surg Oncol; 2012 Jun; 21(2):103-7. PubMed ID: 21764578
[TBL] [Abstract][Full Text] [Related]
13. ARID3B increases ovarian tumor burden and is associated with a cancer stem cell gene signature.
Roy L; Samyesudhas SJ; Carrasco M; Li J; Joseph S; Dahl R; Cowden Dahl KD
Oncotarget; 2014 Sep; 5(18):8355-66. PubMed ID: 25327563
[TBL] [Abstract][Full Text] [Related]
14. Effects of thymosin β4-derived peptides on migration and invasion of ovarian cancer cells.
Yoon HJ; Oh YL; Ko EJ; Kang A; Eo WK; Kim KH; Lee JY; Kim A; Chun S; Kim H; Ock MS; Cha HJ
Genes Genomics; 2021 Aug; 43(8):987-993. PubMed ID: 34170491
[TBL] [Abstract][Full Text] [Related]
15. CD133 and CD44 are universally overexpressed in GIST and do not represent cancer stem cell markers.
Chen J; Guo T; Zhang L; Qin LX; Singer S; Maki RG; Taguchi T; Dematteo R; Besmer P; Antonescu CR
Genes Chromosomes Cancer; 2012 Feb; 51(2):186-95. PubMed ID: 22076958
[TBL] [Abstract][Full Text] [Related]
16. Expression of CD133 in synovial sarcoma.
Terry J; Nielsen T
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):159-65. PubMed ID: 19752721
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of circulating CD133(+) cells in patients with gastric cancer.
Xia P; Song CL; Liu JF; Wang D; Xu XY
Cell Prolif; 2015 Jun; 48(3):311-7. PubMed ID: 25727099
[TBL] [Abstract][Full Text] [Related]
18. Expression of CD133 and other putative stem cell markers in uveal melanoma.
Thill M; Berna MJ; Grierson R; Reinhart I; Voelkel T; Piechaczek C; Galambos P; Jager MJ; Richard G; Lange C; Gehling UM
Melanoma Res; 2011 Oct; 21(5):405-16. PubMed ID: 21900792
[TBL] [Abstract][Full Text] [Related]
19. The relationship of CD133, histone deacetylase 1 and thrombospondin-1 in gastric cancer.
Eto S; Yoshikawa K; Shimada M; Higashijima J; Tokunaga T; Nakao T; Nishi M; Takasu C; Sato H; Kurita N
Anticancer Res; 2015 Apr; 35(4):2071-6. PubMed ID: 25862862
[TBL] [Abstract][Full Text] [Related]
20. Identification of a distinct population of CD133(+)CXCR4(+) cancer stem cells in ovarian cancer.
Cioffi M; D'Alterio C; Camerlingo R; Tirino V; Consales C; Riccio A; Ieranò C; Cecere SC; Losito NS; Greggi S; Pignata S; Pirozzi G; Scala S
Sci Rep; 2015 May; 5():10357. PubMed ID: 26020117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]